Gene expression profiles give insight into the molecular pathology of bone in primary hyperparathyroidism

Bone

Volumn 39, Issue 1, 2006, Pages 189-198

  Reppe, Sjur ^a   Stilgren, Lis ^b   Olstad, Ole K ^c   Brixen, Kim ^b   Nissen Meyer, Lise Sofie ^a   Gautvik, Kaare M ^a,c   Abrahamsen, Bo ^b  

^a UNIVERSITY OF OSLO   (Norway)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Bone remodeling; Gene expression; PTH; PTH RP

Indexed keywords

COLLAGEN TYPE 1; MESSENGER RNA; OSTEOCALCIN; PARATHYROID HORMONE; PROTEINASE; TRANSCRIPTION FACTOR;

ADULT; AGED; ARTICLE; BONE BIOPSY; CLINICAL ARTICLE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FEMALE; GENE CONTROL; GENE EXPRESSION; HUMAN; HYPERPARATHYROIDISM; MALE; ORTHOPEDIC SURGERY; OSTEOLYSIS; REAL TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION INITIATION;

AGED; BIOLOGICAL MARKERS; BIOPSY; BONE AND BONES; BONE REMODELING; CALCIUM; DENSITOMETRY, X-RAY; DNA PROBES; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; HYPERPARATHYROIDISM, PRIMARY; ILIUM; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RNA, MESSENGER; TIME FACTORS;

EID: 33744782286     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2005.12.020     Document Type: Article

References (36)

1. McSheehy P.M., and Chambers T.J. Osteoblastic cells mediate osteoclastic responsiveness to parathyroid hormone. Endocrinology 118 (1986) 824-828
2. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J.Y., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344 (2001) 1434-1441
3. Grey A., Mitnick M.A., Shapses S., Ellison A., Gundberg C., and Insogna K. Circulating levels of interleukin-6 and tumor necrosis factor-alpha are elevated in primary hyperparathyroidism and correlate with markers of bone resorption-A clinical research center study. J. Clin. Endocrinol. Metab. 81 (1996) 3450-3454
4. Guo C.Y., Holland P.A., Jackson B.F., Hannon R.A., Rogers A., Harrison B.J., et al. Immediate changes in biochemical markers of bone turnover and circulating interleukin-6 after parathyroidectomy for primary hyperparathyroidism. Eur. J. Endocrinol. 142 (2000) 451-459
5. Halabe A., and Shohat B. Effect of parathyroid adenoma excision on interleukin-6 (IL-6) and IL-2 receptor levels. Metabolism 49 (2000) 192-194
6. Nakchbandi I.A., Mitnick M.A., Lang R., Gundberg C., Kinder B., and Insogna K. Circulating levels of interleukin-6 soluble receptor predict rates of bone loss in patients with primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 87 (2002) 4946-4951
7. Christiansen P. The skeleton in primary hyperparathyroidism: a review focusing on bone remodeling, structure, mass, and fracture. APMIS Supp. l (2001) 1-52
8. Hesp R., Tellez M., Davidson L., Elton A., and Reeve J. Trabecular and cortical bone in the radii of women with parathyroid adenomata: a greater trabecular deficit, with a preliminary assessment of recovery after parathyroidectomy. Bone Miner. 2 (1987) 301-310
9. Vestergaard P., Mollerup C.L., Frøkjaer V.G., Christiansen P., Blichert-Toft M., and Mosekilde L. Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. BMJ 321 (2000) 598-602
10. Recommended methods for the determination of four enzymes in blood. Scand. J. Clin. Lab. Invest. 33 (1974) 291-306
11. Pan W. A comparative review of statistical methods for discovering differentially expressed genes in replicated microarray experiments. Bioinformatics 18 (2002) 546-554
12. Efron B., and Tibshirani R. Empirical Bayes methods and false discovery rates for microarrays. Genet. Epidemiol. 23 (2002) 70-86
13. Efron B., Tibshirani R., Storey J.D., and Tusher V. Empirical Bayes analysis of a microarray experiment. J. Am. Stat. Assoc. 96 (2001) 1151-1160
14. Yang D., Zakharkin S.O., Page G.P., Brand J.P., Edwards J.W., Bartolucci A.A., et al. Applications of Bayesian statistical methods in microarray data analysis. Am. J. Pharmacogenomics 4 (2004) 53-62
15. Stolovitzky G. Gene selection in microarray data: the elephant, the blind men and our algorithms. Curr. Opin. Struct. Biol. 13 (2003) 370-376
16. Raisz LG. Potential impact of selective cyclooxygenase-2 inhibitors on bone metabolism in health and disease. Am. J. Med. 110 Suppl 3A (2001) 43S-45S
17. Johnson M., Harnish L.K., Nusse R., and Van Hul W. LRP5 and Wnt signaling: a union made for bone. J. Bone Miner. Res. 19 (2004) 1749-1757
18. Matsuo K., and Ray N. Osteoclasts, mononuclear phagocytes, and c-Fos: new insight into osteoimmunology. Keio J. Med. 53 (2004) 78-84
19. Chen D., Zhao M., and Mundy G.R. Bone morphogenetic proteins. Growth Factors 22 4 (2004) 233-241
20. Franchimont N., Wertz S., and Malaise M. Interleukin-6: an osteotropic factor influencing bone formation?. Bone 37 (2005) 601-606
21. Miyakoshi N., Richman C., Qin X., Baylink D.J., and Mohan S. Effects of recombinant insulin-like growth factor-binding protein-4 on bone formation parameters in mice. Endocrinology 140 (1999) 5719-5728
22. Zhang J., Niu C., Ye L., Huang H., He X., Tong W.G., et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 425 (2003) 836-841
23. Mori-Akiyama Y., Akiyama H., Rowitch D.H., and de Crombrugghe B. Sox9 is required for determination of the chondrogenic cell lineage in the cranial neural crest. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 9360-9365
24. Bialek P., Kern B., Yang X., Schrock M., Sosic D., Hong N., et al. A twist code determines the onset of osteoblast differentiation. Dev. Cell 6 (2004) 423-435
25. Otto F., Lubbert M., and Stock M. Upstream and downstream targets of RUNX proteins. J. Cell Biochem. 89 (2003) 9-18
26. Qin L., Qiu P., Wang L., Li X., Swarthout J.T., Soteropoulos P., et al. Gene expression profiles and transcription factors involved in parathyroid hormone signaling in osteoblasts revealed by microarray and bioinformatics. J. Biol. Chem. 278 (2003) 19723-19731
27. Thomas G.P., Bourne A., Eisman J.A., and Gardiner E.M. Species-divergent regulation of human and mouse osteocalcin genes by calciotropic hormones. Exp. Cell Res. 258 (2000) 395-402
28. Santos F.R., Moyses R.M., Montenegro F.L., Jorgetti V., and Noronha I.L. IL-1beta, TNF-alpha, TGF-beta, and bFGF expression in bone biopsies before and after parathyroidectomy. Kidney Int. 63 (2003) 899-907
29. Metcalf D. The unsolved enigmas of leukemia inhibitory factor. Stem. Cells 21 (2003) 5-14
30. Gorny G., Shaw A., and Oursler M.J. IL-6, LIF, and TNF-alpha regulation of GM-CSF inhibition of osteoclastogenesis in vitro. Exp. Cell Res. 294 (2004) 149-158
31. Richards C.D., Langdon C., Deschamps P., Pennica D., and Shaughnessy S.G. Stimulation of osteoclast differentiation in vitro by mouse oncostatin M, leukaemia inhibitory factor, cardiotrophin-1 and interleukin 6: synergy with dexamethasone. Cytokine 12 (2000) 613-621
32. Stilgren L.S., Rettmer E., Eriksen E.F., Hegedus L., Beck-Nielsen H., and Abrahamsen B. Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism. Bone 35 (2004) 256-265
33. Stilgren L.S., Hegedus L.M., Beck-Nielsen H., and Abrahamsen B. Osteoprotegerin levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism. Calcif. Tissue Int. 73 (2003) 210-216
34. Barsony J., and Marx S.J. Receptor-mediated rapid action of 1 alpha,25-dihydroxycholecalciferol: increase of intracellular cGMP in human skin fibroblasts. Proc. Natl. Acad. Sci. U.S.A. 85 (1988) 1223-1226
35. Wiberg K., Ljunghall S., Binderup L., and Ljunggren O. Studies on two new vitamin D analogs, EB 1089 and KH 1060: effects on bone resorption and osteoclast recruitment in vitro. Bone 17 (1995) 391-395
36. Barsony J., McKoy W., DeGrange D.A., Liberman U.A., and Marx S.J. Selective expression of a normal action of the 1,25-dihydroxyvitamin D3 receptor in human skin fibroblasts with hereditary severe defects in multiple actions of that receptor. J. Clin. Invest. 83 (1989) 2093-2101